11:38:45 EDT Sun 23 Jun 2024
Enter Symbol
or Name
USA
CA



Cybin Inc
Symbol CYBN
Shares Issued 743,885,052
Close 2024-04-15 C$ 0.51
Market Cap C$ 379,381,377
Recent Sedar Documents

Cybin receives depressive disorder therapy patent

2024-04-16 12:27 ET - News Release

Mr. Gabriel Fahel reports

CYBIN ANNOUNCES GRANT OF ADDITIONAL U.S. PATENT IN SUPPORT OF ITS CYB003 BREAKTHROUGH THERAPY PROGRAM FOR MAJOR DEPRESSIVE DISORDER

The United States Patent and Trademark Office has granted U.S. patent 11,958,807 in support of Cybin Inc.'s CYB003 program in major depressive disorder (MDD).

The patent, which is expected to provide exclusivity until at least 2041, includes claims to pharmaceutical compositions within the Company's proprietary deuterated psilocybin analog program, CYB003.

"As we continue to advance CYB003, our deuterated psilocybin analog program for the adjunctive treatment of MDD, further protecting our intellectual property through patent protection is an important achievement," said Doug Drysdale, Chief Executive Officer of Cybin. "The strength of our patents supporting CYB003 underscore our commitment to developing innovative, next-generation, commercially scalable therapeutics to address the significant unmet medical need in MDD. With our robust patent portfolio, and the recent Breakthrough Therapy Designation by the U.S. Food and Drug Administration, we are encouraged by our regulatory pathway for CYB003 and are positioned to move quickly to progress the program," concluded Drysdale.

About Cybin

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Cybin's goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.

Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.